|
|
 |
|
Viewing report
|
|
|
|
Cardiovascular Market Drugs and Devices Market: Successes and Cardiovascular Setbacks in the Third Quarter of 2005
Decision Resources, Inc, Dec 2005, Pages: 11
The third quarter of 2005 was a period of conspicuous change for the cardiovascular market. Several significant events affected drugs and devices on the market and in the pipeline.
By examining the most noteworthy of these events in this report, our cardiology team provide a snapshot of important forces driving the cardiovascular market and an analysis of the implications of those forces. We begin by looking at events in the cardiac stent market; several third-quarter events played a key role in shaping this field. We then discuss successes and setbacks for specific agents as they gained regulatory approvals or faced challenges owing to the emergence of study findings or potential generics competition.
Business Implications
- Several significant events affected cardiovascular drugs and devices on the market and in the pipeline during the third quarter of 2005. Events in the cardiac stent market during the quarter played a key role in shaping the competition in this field. In addition, several drugs gained regulatory approval or faced challenges owing to the emergence of study findings or potential generics competition.
- Head-to-head trials published in the third quarter of 2005 generally favored the Cypher drug-eluting stent from Cordis/Johnson & Johnson over Boston Scientific's Taxus Express2 stent. Such studies, together with issues concerning Taxus's quality control and a $598 million expense for a legal settlement, led to persistent woes for Boston Scientific in the quarter. Other important events included Medtronic's launch of the Endeavor stent and the European Commission's approval of J&J's acquisition of medical device maker Guidant.
- Several important approvals of new drugs as well as new indicationsfor already marketed drugs occurred during the third quarter of 2005. The approval of Pfizer's Revatio (sildenafil) and Servier's Procoralan (ivabradine) is likely to have the largest impact on the cardiovascular market.
- Currently marketed drugs that have found success in the cardiovascular market in the past confronted new challenges. Scios's Natrecor (nesiritide) saw its sales drop amid controversy about its widespread, off-label use in the United States in outpatients. Sanofi-Aventis's Lovenox (enoxaparin) will likely face generics competition following patent challenges.
|
|
|
|
